Philip Tsai - 23 Jul 2026 Form 4 Insider Report for Immunome Inc. (IMNM)

Reporting relationship: Chief Technical Officer
Issuer ticker: IMNM
Reported as of: 23 Jul 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 27 Jul 2026, 16:10:15 UTC
Prior SEC filing: 22 Dec 2025
Source filing: View source filing
Reporting owner signature: /s/ Sandra Stoneman, Attorney-in-Fact

Key filing fact

Philip Tsai filed Form 4 for Immunome Inc. (IMNM) on 27 Jul 2026.

Key facts

This page summarizes Philip Tsai's Form 4 filing for Immunome Inc. (IMNM).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 27 Jul 2026, 16:10.

Change

Previous filing in this sequence was filed on 22 Dec 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002026600 Primary reporting owner

Tsai Philip

Relationship: Chief Technical Officer
Address: C/O IMMUNOME, INC., 18702 N. CREEK PARKWAY, SUITE 100, BOTHELL
Signature: /s/ Sandra Stoneman, Attorney-in-Fact
Signature date: 27 Jul 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

IMNM transaction

Common Stock

Award

Transaction value
Shares: +38,250
Change %: +88%
Price: $0.000000^*
Shares after: 81,550
Date: 23 Jul 2026
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

IMNM transaction Derivative

Employee Stock Option (right to buy)

Award

Transaction value
Shares: +76,500
Change %
Price: $0.000000^*
Shares after: 76,500
Date: 23 Jul 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 76,500
Exercise price: $22.01
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Represents the number of shares of the Issuer's common stock ("Common Stock") underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of Common Stock upon settlement. 25% of the RSUs will vest and settle into Common Stock annually on each anniversary of the grant date, subject to the Reporting Person's continuous service through each such vesting date.

Footnote F2

25% of the shares subject to the options vest on July 23, 2027, and one-thirty-sixth (1/36th) of the remaining shares subject to the options shall vest every month thereafter, subject to the Reporting Person's continuous service through each such vesting date.